DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner
Back to Newsroom
Mentioned in this Article

DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner

Thursday, December 12, 2019 8:55 AM
Share this article now
Topic:
Partnerships

COMPANY TO DISCUSS THIS BUSINESS MOVE IN FURTHER DETAIL EARLY NEXT WEEK, SHORTLY THEREAFTER DECN WILL POST FORECASTS ON ITS WEB SITE

LOS ANGELES, CA / ACCESSWIRE / December 12, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

DECN announces today that have accepted a gesture from our proposed partner to include our GenAccord! meter and test strips, and the GenAccord! MS (multi-user system meter and test strips) as a part of the license agreement, now nearing completion. The two GenAccord! product lines will be independently targeted to uninsured and under-insured diabetics, and separately to chain nursing homes and clinics/urgent care locations.

Keith Berman, CEO of DECN commented, "We have definitely decided to have our Taiwanese contract manufacturer to package for us two distinct FDA cleared systems, both systems using the same version test strips (vial packaged, and individually wrapped strips). We are in the process of completing the various forecasts for these three business units and will discuss everything further next week, inclusive of posting our forecasts, which will have already been signed off on by our partners. The direct to patient model will be implemented on Amazon, Walmart and over 1000 other on-line services in early 1Q 2020."

Mr. Berman concluded, "We were happy to see that when we asked our partner to provide a "cocktail napkin" forecast and guaranteed minimum purchases for GenAccord! it became clear to us that the market was looking for a low-end alternative to be sold and serviced by an FDA approved establishment rather than an importer without a large foor prine. We view the GenAccord! multi-user system as a "niche-filler" with great potential. As stated earlier this week we are pleased to announce that we anticipate selling an expected thousands of meters each month on Amazon and Walmart at $8.95 per meter ("buy two meters and keep a spare"), with each customer looking at a 60 day supply of test strips for $49.95. Next week we will put pencil to paper and forecast for interested parties."

ABOUT DECISION DIAGNOSTICS CORP

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company's GenUltimate TBG product is not yet available for sale in the United States or Puerto Rico but is expected to go on sale in select International markets in January 2020.

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of December 11, 2019 regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:

Decision Diagnostics Corp.
Keith Berman (805) 446-2973

[email protected]
www.genultimate.com
www.genultimatetbg.com
www.petsureteststrips.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.

Decision Diagnostics Corp.
Exchange:
Ticker:
OTC PINK
DECN
$0.0000
NaN%
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: